Item type |
学内発行雑誌 / Departmental Bulletin Paper(1) |
公開日 |
2018-09-03 |
タイトル |
|
|
タイトル |
A Long-acting Muscarinic Antagonist (LAMA) Added to an Inhaled Corticosteroid and Long-acting Beta-2 Agonist Versus LAMA Alone in Moderate-to-severe Chronic Obstructive Pulmonary Disease:A Systematic Review and Meta-analysis of Randomized Trials |
言語 |
|
|
言語 |
eng |
資源タイプ |
|
|
資源タイプ |
departmental bulletin paper |
著者 |
ANDO, Koichi
TANAKA, Akihiko
KUSUMOTO, Sojiro
YAMAOKA, Toshimitsu
OHMORI, Tohru
OHNISHI, Tsukasa
INOUE, Shin
SAGARA, Hironori
|
書誌情報 |
The Showa University journal of medical sciences
巻 30,
号 1,
p. 1-9,
発行日 2018-03
|
抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
We assessed the overall efficacy and safety of a long-acting muscarinic antagonist (LAMA) added to an inhaled corticosteroid (ICS) and long-acting beta-2 agonist (LABA) as a combination therapy (LAMA+ICS/LABA) versus LAMA monotherapy in patients with chronic obstructive pulmonary disease (COPD). The overall efficacy and safety of LAMA+ICS/LABA versus LAMA in patients with COPD were assessed by a meta-analysis of randomized controlled trials (RCTs). We identified LAMA+ICS/LABA RCTs by searching PubMed, Scopus, and the Cochrane Library database. Primary efficacy outcomes were changes in forced expiratory volume in 1 second (FEV1.0) from baseline. Incidences of all adverse events (AAEs) were the primary safety outcomes. Pooled estimates are presented as mean differences (MDs) or risk ratios (RRs) with 95% confidence intervals (CIs). Analyses included intention-to-treat cases. Three LAMA+ICS/LABA RCTs met the criteria for inclusion in this study. The MD, RRs, and their 95% CIs regarding changes in FEV1.0 for LAMA+ICS/LABA compared with those of LAMA were 0.08 (0.04 to 0.13); RRs and 95% CIs for AAEs of LAMA+ICS/LABA compared with those of LAMA were 1.03 (0.82 to 1.29). Conclusions: Pulmonary function was significantly improved in the LAMA+ICS/LABA group with no significant increase in AAE risk. These results provide important analysis regarding the overall efficacy and safety of LAMA+ICS/LABA in patients with COPD. |
DOI |
|
|
|
関連識別子 |
10.15369/sujms.30.1 |
出版者 |
|
|
出版者 |
Showa University Society |
ISSN |
|
|
収録物識別子 |
0915-6380 |
出版タイプ |
|
|
出版タイプ |
VoR |